ALK and anaplastic large cell lymphoma: In younger ALK+ALCL patients (n = 78) with normal LDH at the time of diagnosis, adding etoposide to CHOP(-like) regimens enhanced overall response rates and gave superior event-free survival (EFS) (3-year EFS of 91% vs. 57% in CHOEP vs. CHOP-treated patients, respectively).